GlassScriptPhysician profile
Ufuk Vardar
NPI 1922625268
$2,172.91
in general payments reported to CMS, 2019-2025
15 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $90.23 · 2024: $392 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432 · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.50 |
| Education | $638.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $526.93 | 2025 | Ensite, Cardiomems |
| Novartis Pharmaceuticals Corporation | $318.27 | 2025 | |
| Biosense Webster, INC. | $261.08 | 2025 | Carto 3 |
| Boston Scientific Corporation | $132.78 | 2024 | Watchman Flx |
| Amgen INC. | $125.00 | 2025 | Repatha |
| Shockwave Medical, INC | $124.46 | 2025 | |
| Lantheus Medical Imaging, INC. | $114.75 | 2024 | |
| Medtronic, INC. | $109.88 | 2025 | Micra |
| Edwards Lifesciences Corporation | $109.45 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $103.09 | 2023-2025 | Impella |
| Zoll Circulation INC | $103.00 | 2022 | |
| Philips North America LLC | $38.45 | 2025 | Igt Devices Undivided |
| Zimmer Biomet Holdings, INC. | $37.79 | 2025 | Advantagerib |
| Atricure, INC. | $35.51 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.47 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ufuk Vardar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.